Clathrin therapeutic for psychiatric disorders

Abstract

The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic agent for treating psychiatric disorders.

In view of the foregoing, what is claimed is: 
     
         1 . A pharmaceutical composition, comprising at least one of a nanoparticle arrangement (NA) comprised of a plurality of clathrin protein nanoparticles and each NA is not a clathrin protein cage arrangement, each clathrin protein nanoparticle comprising one or more of a full length SEQ ID NO:1 or a humanized variant thereof, and the NA can pass through the blood brain barrier of a subject, and the preceding NA further can treat at least one of a psychiatric disorder, or a condition associated with psychiatric, in the subject. 
     
     
         2 . The composition according to  claim 1 , characterized in that each of the SEQ ID NO:1 is a clathrin heavy chain protein. 
     
     
         3 . The composition according to  claim 2 , characterized in that one or more of a surface of each of the clathrin heavy chain protein is further modified with at least one of a clathrin light chain protein. 
     
     
         4 . The composition according to  claim 2 , characterized in that the clathrin heavy chain protein is one or more of a part of the clathrin heavy chain protein. 
     
     
         5 . The composition according to  claim 1 , characterized in that the clathrin protein nanoparticles consist of a plurality of molecules selected from at least one of biologically active, biologically inert, biologically modified, chemically modified, chiral, cloned, genetically modified, hybridized, isolated, purified, recombinant, synthetic, masked, unmasked molecules. 
     
     
         6 . The composition according to  claim 1 , characterized in that one or more of a surface of the clathrin protein nanoparticles is further modified with at least one biological moiety selected from amino acids, peptides, proteins, neurotransmitters, receptors, adaptor proteins, antibodies, cells, hormones, vitamins, DNA, RNA, RNA variants. 
     
     
         7 . The composition according to  claim 1 , characterized in that one or more of a surface of the clathrin protein nanoparticles is further modified with a multiple of masking moieties. 
     
     
         8 . The composition according to  claim 1 , characterized in that one or more of a surface of the clathrin protein nanoparticles is further modified with a multiple of targeting moieties. 
     
     
         9 . The composition according to  claim 1 , characterized in that the clathrin protein nanoparticles are stable in serum. 
     
     
         10 . The composition according to  claim 1 , characterized in that the clathrin protein nanoparticles are non-immunogenic. 
     
     
         11 . The composition according to  claim 1 , characterized in that the clathrin protein nanoparticles are non-toxic. 
     
     
         12 . The composition according to  claim 1 , characterized in that one or more of a surface of the clathrin protein nanoparticles is further modified with one or more of link element selected from at least one link type consisting of biochemicals, biologicals, biotin-avidin couplers, chemicals, covalent, cross-linkers, electrical, electromagnetic, ESR, fiber optic, functional, Internet, local, logical, molecular bridges, metals, molecular bridges, molecular tethers, MRI, NMR, non-covalent, PEGs, PET, photonic, physical, polymers, quantum mechanical, radio, remote, spacers, ultrasound, wires type. 
     
     
         13 . (canceled) 
     
     
         14 . The composition according to  claim 1 , characterized in that the clathrin protein nanoparticles can pass through at least one of biological barrier type that consists of at least one of blood brain, blood-cerebrospinal, blood vessel, capillary, cell, cell membrane, circumventricular, epithelial, extracellular, fenestrated capillary, fenestrated vessel, intracellular, intramuscular, lipid, lymphatic, nasal, nasal cavity, nasal mucosa, ocular, olfactory epithelium, olfactory nerve, oral, anal, membrane protein, organelle, paracellular, perineural space, plasma membrane, skin, subarachnoid, subcutaneous, tight junction, trigeminal nerve, vomeronasal, vesicle type. 
     
     
         15 . The composition according to  claim 1 , characterized in that the subject is a living human or animal. 
     
     
         16 . The composition according to  claim 1 , characterized in that the composition is a drug. 
     
     
         17 . The drug according to  claim 16 , wherein the drug treats at least one of a psychiatric disorder, or a condition associated with psychiatric, of a subject. 
     
     
         18 . The drug according to  claim 17 , further comprising, treatment of cell and at least one of an endocytosis, exocytosis, genes, growth factors, mitosis, trafficking, signaling, DNA, RNA, or RNA variants. 
     
     
         19 . The drug according to  claim 17 , wherein the subject is a living human or animal. 
     
     
         20 . The drug according to  claim 17 , further characterized in that some portion of the drug is further modified with at least one of an adjunct that provides treatment of psychiatric. 
     
     
         21 . The drug according to  claim 16 , wherein the drug is administered to a subject in need thereof. 
     
     
         22 . A method of treating at least one of a psychiatric disorder, or a condition associated with psychiatric, in a subject, comprising administering, to the subject, a composition of  claim 1 . 
     
     
         23 . The method according to  claim 22 , further comprising, treating cell and at least one of an endocytosis, exocytosis, genes, growth factors, mitosis, trafficking, signaling, DNA, RNA, or RNA variants. 
     
     
         24 . The method according to  claim 22 , wherein the subject is a living human or animal. 
     
     
         25 . A method for a pharmaceutical composition, comprising: forming at least one of a nanoparticle arrangement (NA) comprised of a plurality of clathrin protein nanoparticles and each NA is not a clathrin protein cage arrangement, each clathrin protein nanoparticle comprising one or more of a full length SEQ ID NO:1 or a humanized variant thereof, and the NA can pass through the blood brain barrier of a subject, and, further, using the preceding NA for treating at least one of a psychiatric disorder, or a condition associated with psychiatric, in the subject. 
     
     
         26 . (canceled) 
     
     
         27 . (canceled) 
     
     
         28 . The composition according to  claim 12 , further characterized in that one or more of the link element connects at least one of the nanoparticle arrangement to one or more of operator. 
     
     
         29 . The composition according to  claim 12 , further characterized in that one or more of the link element connects at least one of the nanoparticle arrangement to one or more of device. 
     
     
         30 . The method according to  claim 25 , wherein the subject is a living human or animal. 
     
     
         31 . The composition according to  claim 1 , further characterized in that one or more of a surface of the clathrin protein nanoparticles is further modified with at least one of non-biological element selected from chemicals, crystals, dopants, gases, fluids, metals, optics, polymers, solids, vapors. 
     
     
         32 . The adjunct of  claim 20 , wherein the one or more adjunct element is selected from at least one of adjunct type consisting of age-based, antibiotics, antibacterials, anti-parasitic, antivirals, gender-based, ethnicity-based, chemicals, cosmetics, crystals, cytostatic, drug, dopants, gases, fluids, metabolic, metals, nutrition, optics, polymers, prosthetics, regenerative, solids, vaccines, vapors, large molecules, small molecules, genotype, phenotype, amino acids, peptides, proteins, neurotransmitters, receptors, adaptor proteins, antibodies, cells, growth factors, hormones, vitamins, DNA, RNA, RNA variant type.